IPM Take
Vaccine equity is easiest to promise when nobody is competing for vaccines. The real test arrives when an outbreak starts, manufacturers have finite supply and every additional week of negotiation gives transmission more room.
The new mpox stockpile is therefore important not because it creates another international mechanism, but because it attempts to move allocation decisions upstream. Countries should not have to begin negotiating from zero every time a cluster becomes an emergency.
Executive Summary
WHO, Gavi and partners have launched a global mpox vaccine stockpile under the International Coordinating Group on Vaccine Provision, the mechanism already used for emergency vaccines against cholera, meningitis, yellow fever and Ebola virus disease.
The stockpile was launched on 27 August and is scheduled to begin operations later in September. It is financed by Gavi and will be accessible to all countries for outbreak response. The mechanism builds on the temporary Access and Allocation Mechanism established during the 2024 mpox emergency.
Between January 2022 and July 2026, 145 countries and territories reported 190,683 confirmed mpox cases and 529 deaths, with approximately two thirds of reported cases occurring in the WHO African Region.
Why it matters
- Governments: Countries will have a standing mechanism for requesting emergency vaccine supply rather than having to negotiate access independently during each outbreak.
- Communities: More equitable allocation can reduce the delay between identifying high-risk populations and offering vaccination.
- Industry and global partners: The stockpile requires continued forecasting, procurement and supply planning so an allocation mechanism does not exist without enough product behind it.
The global mpox response has already shown what happens when medical innovation arrives before the architecture required to distribute it fairly. Vaccines existed. Some countries could acquire them quickly. Others entered emergency negotiations while transmission expanded, international partners attempted to assemble donated doses and communities watched a preventable access gap become part of the outbreak itself.
The new global vaccine stockpile is an attempt to stop repeating that sequence.
Managed through the International Coordinating Group on Vaccine Provision and financed by Gavi, the stockpile gives mpox a place alongside cholera, meningitis, yellow fever and Ebola within an established mechanism for emergency vaccine deployment. All countries will be able to request access, with operations expected to begin later this month.
The importance lies in institutional memory. The temporary Access and Allocation Mechanism created during the 2024 mpox emergency showed that global coordination could improve distribution, but it was built in response to a crisis. A standing stockpile changes the starting point. Instead of creating an allocation system while an outbreak is already generating pressure, partners can maintain the mechanism, forecast needs and decide how scarce doses should be directed before urgency distorts the process.
That does not automatically solve vaccine inequity. A stockpile is not a vaccine factory, and equitable rules cannot distribute doses that have not been procured. Manufacturing capacity, financing, regulatory pathways, country requests, delivery logistics and community acceptance all remain critical. The existence of a global mechanism should therefore be judged by how quickly vaccination actually begins when a country reports an outbreak, not by how elegantly the governance structure is described.
The epidemiology gives the mechanism a clear purpose. More than 190,000 confirmed cases were reported globally between the beginning of 2022 and the end of July 2026, and around two thirds of reported cases occurred in Africa. Mpox affects different populations in different settings, while the coexistence of multiple viral clades makes a single global response model increasingly inadequate.
That is also why allocation cannot be based solely on who asks first or who can pay the most. Epidemiological risk, severity, transmission dynamics and the potential impact of vaccination have to shape decisions. A credible stockpile should be most valuable to countries precisely when their domestic purchasing power is least capable of competing with richer markets.
There is a further equity question inside countries. Receiving doses at an airport does not guarantee that they reach the communities driving transmission or those at greatest risk of severe disease. Distribution has to work through trusted services, identify eligible people without stigma and make vaccination practically accessible rather than nominally available.
The international community has spent several years learning that emergency vaccine access cannot be improvised every time a pathogen spreads beyond expectations. Mpox is now being given a permanent mechanism designed around that lesson.
The measure of success will be simple. When the next country needs vaccines urgently, the world should already know where the doses are, who can request them, how they will be allocated and how quickly they can move.
That is what preparedness is supposed to mean.
